{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:27:12Z","timestamp":1792175232844,"version":"4.4.0"},"reference-count":222,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Therapy resistance remains a leading cause of treatment failure and mortality in thoracic malignancies, despite major advances in targeted therapies and immunotherapies. Resistance evolves through heterogeneous, patient-specific mechanisms, including genetic alterations, epigenetic reprogramming, lineage plasticity, and tumor-microenvironment interactions, often emerging before radiographic progression or clinical relapse. Conventional tissue biopsies and imaging, while essential for diagnosis and treatment selection, are limited in their ability to capture spatial and temporal tumor heterogeneity or to support dynamic monitoring of tumor evolution. Liquid biopsy has therefore emerged as a minimally invasive approach for real-time assessment of tumor-derived biomarkers in circulation, enabling longitudinal tracking of resistance biology across the cancer care continuum. In this review, we highlight recent advances in liquid biopsy applications for thoracic malignancies, focusing on circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) as complementary analytes for baseline molecular profiling, detection of primary and acquired resistance to therapy, and identification of minimal residual disease and molecular relapse. Beyond mutation-based approaches, we highlight emerging non-genomic ctDNA features, including epigenomic and fragmentomic signatures, that capture treatment-induced adaptation and lineage plasticity not detectable by conventional plasma genomic profiling, and discuss advances in CTC technologies that preserve cellular and phenotypic context relevant to resistance and metastatic potential. Finally, we examine multimodal liquid biopsy strategies that integrate multiple circulating analytes with artificial intelligence-assisted methods to enhance sensitivity, provide a more comprehensive view of tumor biology, and inform adaptive therapy strategies. We also outline key analytical and clinical challenges that must be addressed through standardized, prospective trials to translate liquid biopsy-guided surveillance and early interception of resistance into improved patient outcomes.<\/jats:p>","DOI":"10.3389\/fonc.2026.1806868","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:43:56Z","timestamp":1786362236000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Liquid biopsies for detection, characterization, and interception of therapy resistance in thoracic malignancies"],"prefix":"10.3389","volume":"16","author":[{"given":"Ezgi","family":"Oner","sequence":"first","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volga","family":"M. Saini","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Research Group, Trinity Translational Medicine Institute, St James\u2019s Hospital","place":["Dublin, Ireland"]},{"name":"Department of Clinical Medicine, School of Medicine, Trinity College Dublin","place":["Dublin, Ireland"]},{"name":"Trinity St. James\u2019s Cancer Institute, Trinity College Dublin","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Cahill","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Research Group, Trinity Translational Medicine Institute, St James\u2019s Hospital","place":["Dublin, Ireland"]},{"name":"Department of Clinical Medicine, School of Medicine, Trinity College Dublin","place":["Dublin, Ireland"]},{"name":"Trinity St. James\u2019s Cancer Institute, Trinity College Dublin","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"O\u2019Toole","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Research Group, Trinity Translational Medicine Institute, St James\u2019s Hospital","place":["Dublin, Ireland"]},{"name":"Department of Clinical Medicine, School of Medicine, Trinity College Dublin","place":["Dublin, Ireland"]},{"name":"Trinity St. James\u2019s Cancer Institute, Trinity College Dublin","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer W.","family":"Li","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]},{"name":"The Lung Cancer Precision Medicine Center of Excellence, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Gately","sequence":"additional","affiliation":[{"name":"Thoracic Oncology Research Group, Trinity Translational Medicine Institute, St James\u2019s Hospital","place":["Dublin, Ireland"]},{"name":"Department of Clinical Medicine, School of Medicine, Trinity College Dublin","place":["Dublin, Ireland"]},{"name":"Trinity St. James\u2019s Cancer Institute, Trinity College Dublin","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valsamo","family":"Anagnostou","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]},{"name":"The Lung Cancer Precision Medicine Center of Excellence, Johns Hopkins University School of Medicine","place":["Baltimore, MD, United States"]},{"name":"The Johns Hopkins Molecular Tumor Board, Johns Hopkins Hospital","place":["Baltimore, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)01635-6","article-title":"The global, regional, and national burden of cancer, 1990\u20132023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023","volume":"406","author":"Force","year":"2025","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.265","article-title":"Understanding and targeting resistance mechanisms in cancer","volume":"4","author":"Lei","year":"2023","journal-title":"Medcomm"},{"key":"B4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","article-title":"Unveiling the mechanisms and challenges of cancer drug resistance","volume":"22","author":"Khan","year":"2024","journal-title":"Cell Commun Signaling"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-21-1606","article-title":"Epigenetic alterations and mechanisms that drive resistance to targeted cancer therapies","volume":"81","author":"Wajapeyee","year":"2021","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/cimb46010050","article-title":"Molecular profiling of circulating tumour cells and circulating tumour DNA: complementary insights from a single blood sample utilising the Parsortix\u00ae system","volume":"46","author":"Wishart","year":"2024","journal-title":"Curr Issues Mol Biol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/bios15020074","article-title":"Dual biomarker strategies for liquid biopsy: integrating circulating tumor cells and circulating tumor DNA for enhanced tumor monitoring","volume":"15","author":"Moon","year":"2025","journal-title":"Biosensors"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/edbk-25-481114","article-title":"Liquid biopsy approaches for cancer characterization, residual disease detection, and therapy monitoring","volume":"45","author":"Aredo","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1158\/2159-8290.cd-25-0164","article-title":"From discovery to diagnosis: a perspective for circulating tumor cells in personalized oncology","volume":"15","author":"Alix-Panabi\u00e8res","year":"2025","journal-title":"Cancer Discov"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-0037","article-title":"Pushing the boundaries of liquid biopsies for early precision intervention","volume":"14","author":"Anagnostou","year":"2024","journal-title":"Cancer Discov"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169006","article-title":"Making the rounds: exploring the role of circulating tumor DNA (ctDNA) in non-small cell lung cancer","volume":"23","author":"Shields","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.4457","article-title":"Practical considerations for the use of circulating tumor DNA in the treatment of patients with cancer: a narrative review","volume":"8","author":"Krebs","year":"2022","journal-title":"JAMA Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3233\/TUB-220044","article-title":"Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: early detection, monitoring and therapy prediction","volume":"46","author":"Duffy","year":"2024","journal-title":"Tumor Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17203327","article-title":"Circulating tumor DNA as a prognostic and predictive biomarker in lung cancer","volume":"17","author":"Dhillon","year":"2025","journal-title":"Cancers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw3616","article-title":"Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies","volume":"372","author":"Lo","year":"2021","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1515\/medgen-2023-2065","article-title":"The changing face of circulating tumor DNA (ctDNA) profiling: factors that shape the landscape of methodologies, technologies, and commercialization","volume":"35","author":"Bronkhorst","year":"2023","journal-title":"Med Gen"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-0143","article-title":"False-positive plasma genotyping due to clonal hematopoiesis","volume":"24","author":"Hu","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04093-9","article-title":"Liquid biopsies across the cancer care continuum","volume":"31","author":"Landon","year":"2025","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1021\/ac202028g","article-title":"High-throughput droplet digital PCR system for absolute quantitation of DNA copy number","volume":"83","author":"Hindson","year":"2011","journal-title":"Anal Chem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci Transl Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-1082","article-title":"Early noninvasive detection of response to targeted therapy in non\u2013small cell lung cancer","volume":"79","author":"Phallen","year":"2019","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.007","article-title":"Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer","volume":"33","author":"Gale","year":"2022","journal-title":"Ann Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28565","article-title":"Analytical validation of NeXT Personal\u00ae, an ultra-sensitive personalized circulating tumor DNA assay","volume":"15","author":"Northcott","year":"2024","journal-title":"Oncotarget"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100540","article-title":"Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels","volume":"7","author":"Ramarao-Milne","year":"2022","journal-title":"ESMO Open"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0915-3","article-title":"Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring","volume":"26","author":"Zviran","year":"2020","journal-title":"Nat Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03040-4","article-title":"Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment","volume":"30","author":"Widman","year":"2024","journal-title":"Nat Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-025-00795-x","article-title":"Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection","volume":"25","author":"Bruhm","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1038\/s41467-021-24994-w","article-title":"Detection and characterization of lung cancer using cell-free DNA fragmentomes","volume":"12","author":"Mathios","year":"2021","journal-title":"Nat Commun"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1272-6","article-title":"Genome-wide cell-free DNA fragmentation in patients with cancer","volume":"570","author":"Cristiano","year":"2019","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-0519","article-title":"Clinical validation of a cell-free DNA fragmentome assay for augmentation of lung cancer early detection","volume":"14","author":"Mazzone","year":"2024","journal-title":"Cancer Discov"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-023-01446-3","article-title":"Single-molecule genome-wide mutation profiles of cell-free DNA for non-invasive detection of cancer","volume":"55","author":"Bruhm","year":"2023","journal-title":"Nat Genet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2018.387","article-title":"A phase II trial of osimertinib in the second-line treatment of non-small cell lung cancer with the EGFR T790M mutation, detected from circulating tumor DNA: LiquidLung-O-Cohort 2","volume":"51","author":"Park","year":"2019","journal-title":"Cancer Res Treat"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.02.012","article-title":"Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial","volume":"34","author":"Remon","year":"2023","journal-title":"Ann Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00498-4","article-title":"Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial","volume":"25","author":"Provencio","year":"2024","journal-title":"Lancet Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3390\/app10082895","article-title":"Performance of the OncomineTM Lung cfDNA Assay for liquid biopsy by NGS of NSCLC patients in routine laboratory practice","volume":"10","author":"De Luca","year":"2020","journal-title":"Appl Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/po.18.00299","article-title":"Prospective clinical validation of the InVisionFirst-Lung circulating tumor DNA assay for molecular profiling of patients with advanced nonsquamous non\u2013small-cell lung cancer","volume":"3","author":"Pritchett","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.10.007","article-title":"Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib","volume":"166","author":"Bauml","year":"2022","journal-title":"Lung Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0237802","article-title":"Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin","volume":"15","author":"Woodhouse","year":"2020","journal-title":"PloS One"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.16_suppl.3057","article-title":"Resolution ctDx FIRST plasma assay as a companion diagnostic for adagrasib and its application to longitudinal monitoring","volume":"40","author":"Pekker","year":"2022","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13905","article-title":"Validation of a circulating tumor DNA-based next-generation sequencing assay in a cohort of patients with solid tumors: a proposed solution for decentralized plasma testing","volume":"26","author":"Al Zoughbi","year":"2021","journal-title":"Oncologist"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2019.10.013","article-title":"Concordance of genomic alterations by next-generation sequencing in tumor tissue versus cell-free DNA in stage I\u2013IV non\u2013small cell lung cancer","volume":"22","author":"Jiang","year":"2020","journal-title":"J Mol Diagn"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02047-z","article-title":"Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer","volume":"28","author":"Jee","year":"2022","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-1127","article-title":"Dynamics of tumor and immune responses during immune checkpoint blockade in non\u2013small cell lung cancer","volume":"79","author":"Anagnostou","year":"2019","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1078-0432.ccr-23-1469","article-title":"Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer","volume":"30","author":"Murray","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-2242","article-title":"Dynamics of sequence and structural cell-free DNA landscapes in small-cell lung cancer","volume":"29","author":"Sivapalan","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02877-z","article-title":"Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal\/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nature12065","article-title":"Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA","volume":"497","author":"Murtaza","year":"2013","journal-title":"Nature"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat Commun"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00317","article-title":"Whole exome sequencing of cell-free DNA for early lung cancer: a pilot study to differentiate benign from Malignant CT-detected pulmonary lesions","volume":"9","author":"Tailor","year":"2019","journal-title":"Front Oncol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000527","article-title":"Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression","volume":"8","author":"Leprieur","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262211111","article-title":"Copy number alteration profiling from plasma cfDNA WES in advanced NSCLC","volume":"26","author":"Jang","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105894","article-title":"Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board","volume":"10","author":"Krieghoff-Henning","year":"2025","journal-title":"ESMO Open"},{"key":"B58","article-title":"Liquid biopsy approaches to capture minimal residual disease and therapy response in patients with early stage cancers","volume-title":"International Review of Cell and Molecular Biology","author":"Landon","year":"2024"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3729","article-title":"Anchored multiplex PCR for targeted next-generation sequencing","volume":"20","author":"Zheng","year":"2014","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03958-3","article-title":"Perioperative nivolumab or nivolumab plus ipilimumab in resectable diffuse pleural mesothelioma: a phase 2 trial and ctDNA analyses","volume":"31","author":"Reuss","year":"2025","journal-title":"Nat Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00115-0","article-title":"Ultra-sensitive molecular residual disease detection through whole genome sequencing with single-read error correction","volume":"16","author":"Li","year":"2024","journal-title":"EMBO Mol Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12916-023-02954-z","article-title":"Individualized dynamic methylation-based analysis of cell-free DNA in postoperative monitoring of lung cancer","volume":"21","author":"Chen","year":"2023","journal-title":"BMC Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-22-0363","article-title":"Enhanced detection of landmark minimal residual disease in lung cancer using cell-free DNA fragmentomics","volume":"3","author":"Wang","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008028","article-title":"Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non-small cell lung cancer","volume":"12","author":"Guler","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s13148-022-01387-4","article-title":"Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients","volume":"14","author":"Janke","year":"2022","journal-title":"Clin Epigenet"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-24-0466","article-title":"Detecting small cell transformation in patients with advanced EGFR mutant lung adenocarcinoma through epigenomic cfDNA profiling","volume":"30","author":"El Zarif","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.2139\/ssrn.3441815","article-title":"Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients","volume":"8","author":"Xia","year":"2019","journal-title":"Trans Lung Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1137384","article-title":"Monitoring EGFR-lung cancer evolution: a possible beginning of a \u201cmethylation era\u201d in TKI resistance prediction","volume":"13","author":"Fabrizio","year":"2023","journal-title":"Front Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-021-00746-5","article-title":"Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning","volume":"5","author":"Liang","year":"2021","journal-title":"Nat BioMed Eng"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s12276-023-01119-5","article-title":"Cancer signature ensemble integrating cfDNA methylation, copy number, and fragmentation facilitates multi-cancer early detection","volume":"55","author":"Kim","year":"2023","journal-title":"Exp Mol Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1101\/gr.266551.120","article-title":"Enzymatic methyl sequencing detects DNA methylation at single-base resolution from picograms of DNA","volume":"31","author":"Vaisvila","year":"2021","journal-title":"Genome Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-25-0151","article-title":"Methylation-based ctDNA tumor fraction changes predict long-term clinical benefit from immune checkpoint inhibitors in RADIOHEAD, a real-world pan-cancer study","volume":"5","author":"Liang","year":"2025","journal-title":"Cancer Res Commun"},{"key":"B74","doi-asserted-by":"publisher","first-page":"100442","DOI":"10.1016\/j.jlb.2025.100442","article-title":"Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid Malignancies","volume":"10","author":"Rolfo","year":"2025","journal-title":"J Liquid Biopsy"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.05.806","article-title":"Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set","volume":"32","author":"Klein","year":"2021","journal-title":"Ann Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1038\/s41467-024-47886-1","article-title":"Multimodal analysis of cfDNA methylomes for early detecting esophageal squamous cell carcinoma and precancerous lesions","volume":"15","author":"Liu","year":"2024","journal-title":"Nat Commun"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-019-0202-2","article-title":"Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA","volume":"14","author":"Shen","year":"2019","journal-title":"Nat Protoc"},{"key":"B78","doi-asserted-by":"publisher","first-page":"8801","DOI":"10.1016\/j.annonc.2024.08.073","article-title":"Cancer treatment monitoring using cell-free DNA fragmentomes","volume":"15","author":"van\u2019t Erve","year":"2024","journal-title":"Nat Commun"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01370-3","article-title":"A deep-learning model for quantifying circulating tumour DNA from the density distribution of DNA-fragment lengths","volume":"9","author":"Zhu","year":"2025","journal-title":"Nat BioMed Eng"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101349","article-title":"Multi-modal cell-free DNA genomic and fragmentomic patterns enhance cancer survival and recurrence analysis","volume":"5","author":"Moldovan","year":"2024","journal-title":"Cell Rep Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17213474","article-title":"Liquid biopsy in lung cancer: Tracking resistance to targeted therapies","volume":"17","author":"Urtecho","year":"2025","journal-title":"Cancers"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01011-3","article-title":"Utilizing ctDNA to discover mechanisms of resistance to targeted therapies in patients with metastatic NSCLC: towards more informative trials","volume":"22","author":"Ernst","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-25-0561","article-title":"Serial plasma comprehensive genomic profiling captures therapy resistance and guides management of non-small cell lung cancer","volume":"6","author":"Conroy","year":"2026","journal-title":"Cancer Res Commun"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant osimertinib for resectable EGFR-mutated non\u2013small cell lung cancer","volume":"43","author":"He","year":"2025","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2403614","article-title":"Amivantamab plus lazertinib in previously untreated EGFR-mutated advanced NSCLC","volume":"391","author":"Cho","year":"2024","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2463880","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"B89","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2025.100076","article-title":"Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers","volume-title":"Pharmacological Reviews","author":"Du","year":"2025"},{"key":"B90","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume-title":"British Journal of Cancer","author":"Leonetti","year":"2019"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-1406","article-title":"INSIGHT 2: A phase II study of tepotinib plus osimertinib in MET-amplified NSCLC and first-line osimertinib resistance","volume":"18","author":"Smit","year":"2022","journal-title":"Future Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up\u2605","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.398","article-title":"360P ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib","volume":"33","author":"Piotrowska","year":"2022","journal-title":"Ann Oncol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13148-025-01870-8","article-title":"Plasma cell-free DNA methylation profile before afatinib treatment is associated with progression-free and overall survival of patients with epidermal growth factor receptor gene mutation-positive non-small cell lung cancer","volume":"17","author":"Fujimoto","year":"2025","journal-title":"Clin Epigenet"},{"key":"B96","doi-asserted-by":"publisher","first-page":"16436","DOI":"10.1038\/s41598-021-95985-6","article-title":"Liquid biopsy uncovers distinct patterns of DNA methylation and copy number changes in NSCLC patients with different EGFR-TKI resistant mutations","volume":"11","author":"Nguyen","year":"2021","journal-title":"Sci Rep"},{"key":"B97","unstructured":"List of cleared or approved companion diagnostic devices (In vitro and imaging tools) 2026\n          \n          \n          \n          2026"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2018.10.004","article-title":"Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies","volume":"126","author":"Wu","year":"2018","journal-title":"Lung Cancer"},{"key":"B99","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41467-023-35961-y","article-title":"Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41467-023-35962-x","article-title":"Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial","volume":"14","author":"Chmielecki","year":"2023","journal-title":"Nat Commun"},{"key":"B101","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jmoldx.2023.10.002","article-title":"Pan-tumor analytical validation and osimertinib clinical validation in EGFR mutant non\u2013small-cell lung cancer, supporting the first next-generation sequencing liquid biopsy in vitro diagnostic","volume":"26","author":"Gray","year":"2024","journal-title":"J Mol Diagn"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.089","article-title":"Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO scale for clinical actionability of molecular targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)","volume":"33","author":"Bayle","year":"2022","journal-title":"Ann Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.1779","article-title":"Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer: a nonrandomized controlled trial","volume":"10","author":"Dong","year":"2024","journal-title":"JAMA Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007309","article-title":"Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development","volume":"11","author":"Tawbi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.2147\/ITT.S567238","article-title":"Emerging predictive biomarkers of immunotherapy sensitivity in patients with non-small cell lung cancer","volume":"15","author":"Gariazzo","year":"2026","journal-title":"ImmunoTargets Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005924","article-title":"Liquid biopsy approaches to capture tumor evolution and clinical outcomes during cancer immunotherapy","volume":"11","author":"Sivapalan","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07943-7","article-title":"CTLA4 blockade abrogates KEAP1\/STK11-related resistance to PD-(L)1 inhibitors","volume":"635","author":"Skoulidis","year":"2024","journal-title":"Nature"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-20-0047","article-title":"Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade","volume":"10","author":"Zhang","year":"2020","journal-title":"Cancer Discov"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02598-9","article-title":"ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results","volume":"29","author":"Anagnostou","year":"2023","journal-title":"Nat Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1200\/po.21.00372","article-title":"Changes in circulating tumor DNA reflect clinical benefit across multiple studies of patients with non\u2013small-cell lung cancer treated with immune checkpoint inhibitors","volume":"6","author":"Vega","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001504","article-title":"Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)","volume":"9","author":"Ricciuti","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00699-2","article-title":"Exploiting temporal aspects of cancer immunotherapy","volume":"24","author":"Zemek","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/cells13080715","article-title":"5-hydroxymethylcytosine in cell-free DNA predicts immunotherapy response in lung cancer","volume":"13","author":"Shao","year":"2024","journal-title":"Cells"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2024.10.013","article-title":"Brief report: Methylation-based ctdna serial monitoring correlates with immunotherapy response in NSCLC","volume":"26","author":"Hsiao","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-22-106","article-title":"Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients","volume":"11","author":"Yue","year":"2022","journal-title":"Trans Lung Cancer Res"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502931","article-title":"Overall survival with neoadjuvant nivolumab plus chemotherapy in lung cancer","volume":"393","author":"Forde","year":"2025","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03216-y","article-title":"Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma","volume":"31","author":"Black","year":"2025","journal-title":"Nat Med"},{"key":"B118","article-title":"A case of cancer in which cells similar to those in the tumours were seen in the blood after death","volume":"14","author":"Ashworth","year":"1869","journal-title":"Aust Med J"},{"key":"B119","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/2159-8290.cd-18-0065","article-title":"Homophilic CD44 interactions mediate tumor cell aggregation and polyclonal metastasis in patient-derived breast cancer models","volume":"9","author":"Liu","year":"2019","journal-title":"Cancer Discov"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2014.07.013","article-title":"Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis","volume":"158","author":"Aceto","year":"2014","journal-title":"Cell"},{"key":"B121","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2217\/14796694.2.5.627","article-title":"Tumor dormancy and metastasis","volume":"102","author":"Hedley","year":"2009","journal-title":"Adv Cancer Res"},{"key":"B122","doi-asserted-by":"crossref","DOI":"10.1097\/00000658-191903000-00014","volume-title":"Neoplastic Diseases: A Treatise on Tumors","author":"Ewing","year":"1919"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116449","article-title":"Deciphering genomic evolution of metastatic organotropism with 535 paired primary lung cancers and metastases","volume":"44","author":"Xie","year":"2025","journal-title":"Cell Rep"},{"key":"B124","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12967-020-02696-z","article-title":"Transcriptomic analysis identifies organ-specific metastasis genes and pathways across different primary sites","volume":"19","author":"Zhang","year":"2021","journal-title":"J\u00a0Transl Med"},{"key":"B125","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41392-021-00817-8","article-title":"Circulating tumor cells: biology and clinical significance","volume":"6","author":"Lin","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-18-0584","article-title":"Circulating tumor cells with stemness and epithelial-to-mesenchymal transition features are chemoresistant and predictive of poor outcome in metastatic breast cancer","volume":"18","author":"Papadaki","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"B127","doi-asserted-by":"publisher","first-page":"11775","DOI":"10.1038\/s41598-023-38881-5","article-title":"Plasticity of circulating tumor cells in small cell lung cancer","volume":"13","author":"Seo","year":"2023","journal-title":"Sci Rep"},{"key":"B128","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.bj.2019.11.002","article-title":"Bring along your friends: Homotypic and heterotypic circulating tumor cell clustering to accelerate metastasis","volume":"43","author":"Aceto","year":"2020","journal-title":"BioMed J"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13163923","article-title":"The liquid biopsy for lung cancer: State of the art, limitations and future developments","volume":"13","author":"Di Capua","year":"2021","journal-title":"Cancers"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2025.07.008","article-title":"Circulating tumor cells: Blood-based detection, molecular biology, and clinical applications","volume":"43","author":"Dai","year":"2025","journal-title":"Cancer Cell"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.14670\/HH-18-924","article-title":"Liquid biopsy of circulating tumor cells: From isolation, enrichment, and genome sequencing to clinical applications","volume":"40","author":"Tan","year":"2025","journal-title":"Histol Histopathol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.molonc.2015.12.002","article-title":"Challenges in circulating tumor cell detection by the CellSearch system","volume":"10","author":"Andree","year":"2016","journal-title":"Mol Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-09-1095","article-title":"Circulating tumor cell as a diagnostic marker in primary lung cancer","volume":"15","author":"Tanaka","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.33.3716","article-title":"Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer","volume":"30","author":"Hou","year":"2012","journal-title":"J Clin Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.28.7045","article-title":"Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer","volume":"29","author":"Krebs","year":"2011","journal-title":"J Clin Oncol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0b013e31823c5c16","article-title":"Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and -independent approaches","volume":"7","author":"Krebs","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s12943-024-01984-2","article-title":"Diagnostic leukapheresis reveals distinct phenotypes of NSCLC circulating tumor cells","volume":"23","author":"Rieckmann","year":"2024","journal-title":"Mol Cancer"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03681-9","article-title":"Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC","volume":"148","author":"Zhang","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-013-3399-2","article-title":"Circulating tumor cells (CTCs) in Malignant pleural mesothelioma (MPM)","volume":"21","author":"Yoneda","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx636","article-title":"Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer","volume":"29","author":"Ili\u00e9","year":"2018","journal-title":"Ann Oncol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12040896","article-title":"Detection of circulating tumor cells in the diagnostic leukapheresis product of non-small-cell lung cancer patients comparing CellSearch(\u00ae) and ISET","volume":"12","author":"Tamminga","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061556","article-title":"Optimization of the enrichment of circulating tumor cells for downstream phenotypic analysis in patients with non-small cell lung cancer treated with anti-PD-1 immunotherapy","volume":"12","author":"Papadaki","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060835","article-title":"Determination of PD-L1 expression in circulating tumor cells of NSCLC patients and correlation with response to PD-1\/PD-L1 inhibitors","volume":"11","author":"Janning","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s449777","article-title":"Linking EMT status of circulating tumor cells to clinical outcomes in lung cancer","volume":"16","author":"Huangfu","year":"2024","journal-title":"Cancer Manag Res"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1038\/nature06385","article-title":"Isolation of rare circulating tumour cells in cancer patients by microchip technology","volume":"450","author":"Nagrath","year":"2007","journal-title":"Nature"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.3390\/cells9040888","article-title":"Detection of circulating tumor cells (CTCs) in Malignant pleural mesothelioma (MPM) with the \"Universal\" CTC-Chip and an anti-podoplanin antibody NZ-1.2","volume":"9","author":"Kuwata","year":"2020","journal-title":"Cells"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-1329","article-title":"Clinical significance of circulating tumor cells in hormone receptor-positive metastatic breast cancer patients who received letrozole with or without bevacizumab","volume":"26","author":"Magbanua","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617032114","article-title":"An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma","volume":"114","author":"Kalinich","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3973","article-title":"Multiplexed quantification of proteins and transcripts in single cells","volume":"35","author":"Peterson","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-16-3072","article-title":"Circulating tumor cells with aberrant ALK copy number predict progression-free survival during crizotinib treatment in ALK-rearranged non-small cell lung cancer patients","volume":"77","author":"Pailler","year":"2017","journal-title":"Cancer Res"},{"key":"B151","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1038\/s41598-017-02217-x","article-title":"Droplet digital PCR versus qPCR for gene expression analysis with low abundant targets: from variable nonsense to publication quality data","volume":"7","author":"Taylor","year":"2017","journal-title":"Sci Rep"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231192401","article-title":"Advances in novel strategies for isolation, characterization, and analysis of CTCs and ctDNA","volume":"15","author":"Yaghoubi Naei","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3390\/cimb44020052","article-title":"Single circulating-tumor-cell-targeted sequencing to identify somatic variants in liquid biopsies in non-small-cell lung cancer patients","volume":"44","author":"Barbirou","year":"2022","journal-title":"Curr Issues Mol Biol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.12901","article-title":"Circulating tumor cell profiling for precision oncology","volume":"15","author":"Labib","year":"2021","journal-title":"Mol Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2072-1439.2012.09.02","article-title":"Biology and clinical relevance of circulating tumour cells","volume":"4","author":"Carter","year":"2012","journal-title":"J Thorac Dis"},{"key":"B156","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1186\/s12967-019-2035-8","article-title":"Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer","volume":"17","author":"Shishido","year":"2019","journal-title":"J Transl Med"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3390\/cancers6010153","article-title":"Evaluation of circulating tumor cells and related events as prognostic factors and surrogate biomarkers in advanced NSCLC patients receiving first-line systemic treatment","volume":"6","author":"Muinelo-Romay","year":"2014","journal-title":"Cancers (Basel)"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.05.002","article-title":"Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer","volume":"85","author":"Normanno","year":"2014","journal-title":"Lung Cancer"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds138","article-title":"Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor","volume":"23","author":"Hiltermann","year":"2012","journal-title":"Ann Oncol"},{"key":"B160","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.lungcan.2016.04.014","article-title":"A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer","volume":"99","author":"Pietanza","year":"2016","journal-title":"Lung Cancer"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2024.05.005","article-title":"Clustered circulating tumor cells as a predictor of adjuvant-chemotherapy efficacy in lung cancer","volume":"118","author":"Sawabata","year":"2024","journal-title":"Ann Thorac Surg"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101575","article-title":"The complexities of metastasis","volume":"11","author":"San Juan","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B163","doi-asserted-by":"publisher","first-page":"5337","DOI":"10.1038\/s41598-017-05562-z","article-title":"Small cell lung cancer: model of circulating tumor cell tumorospheres in chemoresistance","volume":"7","author":"Klameth","year":"2017","journal-title":"Sci Rep"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.16818","article-title":"Sensitive detection of viable circulating tumor cells using a novel conditionally telomerase-selective replicating adenovirus in non-small cell lung cancer patients","volume":"8","author":"Togo","year":"2017","journal-title":"Oncotarget"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.722078","article-title":"Whole-exome sequencing on circulating tumor cells explores platinum-drug resistance mutations in advanced non-small cell lung cancer","volume":"12","author":"Chang","year":"2021","journal-title":"Front Genet"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4239","article-title":"Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer","volume":"23","author":"Carter","year":"2017","journal-title":"Nat Med"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.04.001","article-title":"PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab","volume":"120","author":"Guibert","year":"2018","journal-title":"Lung Cancer"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/srep31726","article-title":"Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor nivolumab","volume":"6","author":"Nicolazzo","year":"2016","journal-title":"Sci Rep"},{"key":"B169","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12957-023-03215-2","article-title":"Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis","volume":"21","author":"Cui","year":"2023","journal-title":"World J Surg Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11060806","article-title":"PD-L1 expression with epithelial mesenchymal transition of circulating tumor cells is associated with poor survival in curatively resected non-small cell lung cancer","volume":"11","author":"Manjunath","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2017.1315488","article-title":"PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: a molecular shield to evade immune system","volume":"6","author":"Raimondi","year":"2017","journal-title":"Oncoimmunology"},{"key":"B172","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13578-024-01283-9","article-title":"Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer","volume":"14","author":"Chen","year":"2024","journal-title":"Cell Biosci"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13765","article-title":"Integrative analysis of circulating tumor cells (CTCs) and exosomes from small-cell lung cancer (SCLC) patients: a comprehensive approach","volume":"19","author":"Papakonstantinou","year":"2025","journal-title":"Mol Oncol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010146","article-title":"ES-SCLC patients with PD-L1(+) CTCs and high percentages of CD8(+)PD-1(+)T cells in circulation benefit from front-line immunotherapy treatment","volume":"12","author":"Xagara","year":"2024","journal-title":"Biomedicines"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.3390\/cells8080880","article-title":"Molecular characterization of circulating tumor cells enriched by a microfluidic platform in patients with small-cell lung cancer","volume":"8","author":"Obermayr","year":"2019","journal-title":"Cells"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-25-1483","article-title":"Circulating tumor cells predict response to the DLL3-targeting bispecific antibody tarlatamab","volume":"16","author":"Mishra","year":"2026","journal-title":"Cancer Discov"},{"key":"B178","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12951-025-03522-8","article-title":"Targeting circulating tumor cell\u2013neutrophil interactions: nanoengineered strategies for inhibiting cancer metastasis","volume":"23","author":"Su","year":"2025","journal-title":"J Nanobiotechnology"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-100","article-title":"Comprehensive analysis of blood-based biomarkers for predicting immunotherapy benefits in patients with advanced non-small cell lung cancer","volume":"10","author":"Park","year":"2021","journal-title":"Transl Lung Cancer Res"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.3727\/096504017x14928634401178","article-title":"Circulating tumor cells predict prognosis following tyrosine kinase inhibitor treatment in EGFR-mutant non-small cell\u00a0lung cancer patients","volume":"25","author":"Yang","year":"2017","journal-title":"Oncol Res"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s115221","article-title":"Correlation between epidermal growth factor receptor tyrosine kinase inhibitor efficacy and circulating tumor cell levels in patients with advanced non-small cell lung cancer","volume":"9","author":"He","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0800668","article-title":"Detection of mutations in EGFR in circulating lung-cancer cells","volume":"359","author":"Maheswaran","year":"2008","journal-title":"N Engl J Med"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-15-1031","article-title":"Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses","volume":"22","author":"Sundaresan","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1320659110","article-title":"Reproducible copy number variation patterns among single circulating tumor cells of lung cancer patients","volume":"110","author":"Ni","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.44.5932","article-title":"Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer","volume":"31","author":"Pailler","year":"2013","journal-title":"J Clin Oncol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezx127","article-title":"Long-term survival outcome after postoperative recurrence of non-small-cell lung cancer: who is \u2018cured\u2019 from postoperative recurrence","volume":"52","author":"Sekihara","year":"2017","journal-title":"Eur J Cardio-Thoracic Surg"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-24-942","article-title":"Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: a narrative review","volume":"14","author":"Wang","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1016\/j.pccm.2023.04.001","article-title":"Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer","volume":"1","author":"Tang","year":"2023","journal-title":"Chin Med J Pulm Crit Care Med"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2025.100297","article-title":"Enhancing detection and monitoring of circulating tumor cells: integrative approaches in liquid biopsy advances","volume":"8","author":"Velpula","year":"2025","journal-title":"J Liq Biopsy"},{"key":"B190","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13045-024-01637-3","article-title":"Dynamically monitoring minimal residual disease using circulating tumour cells to predict the recurrence of early-stage lung adenocarcinoma","volume":"17","author":"Zhang","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1200\/PO-24-00709","article-title":"Integrating pathologic stage and perioperative circulating tumor cell variations: early relapse prediction model for resectable non\u2013small cell lung cancer","volume":"9","author":"Fu","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10030144","article-title":"Circulating tumor cells as a tool of minimal residual disease can predict lung cancer recurrence: a longitudinal, prospective trial","volume":"10","author":"Wu","year":"2020","journal-title":"Diagnostics"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlb.2023.100132","article-title":"Cellular residual disease (CRD) in early breast cancer -expanding the concept of minimal residual disease monitoring","volume":"3","author":"Serafini","year":"2024","journal-title":"J Liq Biopsy"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-13-1014","article-title":"Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA","volume":"4","author":"Haber","year":"2014","journal-title":"Cancer Discov"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.572895","article-title":"Detection of EGFR mutations in cfDNA and CTCs, and comparison to tumor tissue in non-small-cell-lung-cancer (NSCLC) patients","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3390\/cells9020522","article-title":"Detection of MET alterations using cell free DNA and circulating tumor cells from cancer patients","volume":"9","author":"Mondelo-Mac\u00eda","year":"2020","journal-title":"Cells"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13235974","article-title":"DNA methylation analysis in plasma cell-free DNA and paired CTCs of NSCLC patients before and after osimertinib treatment","volume":"13","author":"Ntzifa","year":"2021","journal-title":"Cancers"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1435537","article-title":"Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment","volume":"14","author":"Ntzifa","year":"2024","journal-title":"Front Oncol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8071011","article-title":"Prognostic relevance of circulating tumor cells and circulating cell-free DNA association in metastatic non-small cell lung cancer treated with nivolumab","volume":"8","author":"Alama","year":"2019","journal-title":"J Clin Med"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13094","article-title":"Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab","volume":"15","author":"Mondelo-Mac\u00eda","year":"2021","journal-title":"Mol Oncol"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e09971","article-title":"Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer","volume":"8","author":"Kapeleris","year":"2022","journal-title":"Heliyon"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.698551","article-title":"Complementary sequential circulating tumor cell (CTC) and cell-free tumor DNA (ctDNA) profiling reveals metastatic heterogeneity and genomic changes in lung cancer and breast cancer","volume":"11","author":"Kong","year":"2021","journal-title":"Front Oncol"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15061877","article-title":"Preoperative mutational analysis of circulating tumor cells (CTCs) and plasma-cfDNA provides complementary information for early prediction of relapse: A pilot study in early-stage non-small cell lung cancer","volume":"15","author":"Markou","year":"2023","journal-title":"Cancers"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.10.007","article-title":"Profiling of circulating free DNA using targeted and genome-wide sequencing in patients with SCLC","volume":"15","author":"Mohan","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061574","article-title":"Effect of osimertinib on CTCs and ctDNA in EGFR mutant non-small cell lung cancer patients: the prognostic relevance of liquid biopsy","volume":"14","author":"Kallergi","year":"2022","journal-title":"Cancers"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18051035","article-title":"Circulating cell-free DNA and circulating tumor cells as prognostic and predictive biomarkers in advanced non-small cell lung cancer patients treated with first-line chemotherapy","volume":"18","author":"Coco","year":"2017","journal-title":"Int J Mol Sci"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.117.193201","article-title":"Circulating tumor DNA reflects tumor metabolism rather than tumor burden in chemotherapy-naive patients with advanced non\u2013small cell lung cancer: 18F-FDG PET\/CT study","volume":"58","author":"Morbelli","year":"2017","journal-title":"J Nucl Med"},{"key":"B208","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41416-023-02491-9","article-title":"Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer","volume":"130","author":"Eslami-S","year":"2024","journal-title":"Br J Cancer"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32056","article-title":"Single tube liquid biopsy for advanced non\u2010small cell lung cancer","volume":"144","author":"de Wit","year":"2019","journal-title":"Int J Cancer"},{"key":"B210","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s13046-025-03387-7","article-title":"Cancer-associated fibroblasts as a potential novel liquid biopsy marker in cancer patients","volume":"44","author":"Weber","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004688","article-title":"Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy","volume":"10","author":"Hwang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non\u2013small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov"},{"key":"B213","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.canlet.2021.05.009","article-title":"Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives","volume":"514","author":"Zhang","year":"2021","journal-title":"Cancer Lett"},{"key":"B214","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1186\/s12885-020-07376-1","article-title":"Chemotherapy-induced release of circulating-tumor cells into the bloodstream in collective migration units with cancer-associated fibroblasts in metastatic cancer patients","volume":"20","author":"Ortiz-Otero","year":"2020","journal-title":"BMC Cancer"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1016\/j.adcanc.2023.100095","article-title":"Identification and clinical implications of circulating cancer associated fibroblasts in lung cancer patients","volume":"7","author":"Mirza","year":"2023","journal-title":"Adv Cancer Biol - Metastasis"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17193165","article-title":"Artificial intelligence-enhanced liquid biopsy and radiomics in early-stage lung cancer detection: A precision oncology paradigm","volume":"17","author":"Cherukuri","year":"2025","journal-title":"Cancers"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-02048-2","article-title":"Integrative analysis of multi-omics data for liquid biopsy","volume":"128","author":"Chen","year":"2023","journal-title":"Br J Cancer"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-24-1704","article-title":"Integrating ctDNA analysis and radiomics for dynamic risk assessment in localized lung cancer","volume":"15","author":"Moding","year":"2025","journal-title":"Cancer Discov"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2023.115803","article-title":"Analytical validation of the PROphet test for treatment decision-making guidance in metastatic non-small cell lung cancer","volume":"238","author":"Ben","year":"2024","journal-title":"J Pharm BioMed Anal"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1200\/po.23.00555","article-title":"Plasma proteome\u2013based test for first-line treatment selection in metastatic non\u2013small cell lung cancer","volume":"8","author":"Christopoulos","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1172\/jci154941","article-title":"Circulating tumor DNA: current challenges for clinical utility","volume":"132","author":"Dang","year":"2022","journal-title":"J Clin Invest"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105636","article-title":"Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop","volume":"114","author":"de Jager","year":"2025","journal-title":"EBioMedicine"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1806868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T11:44:03Z","timestamp":1786362243000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1806868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":222,"alternative-id":["10.3389\/fonc.2026.1806868"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1806868","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1806868"}}